Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prilosec OTC backs NFL "Protectors" award

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble announces its omeprazole-containing proton pump inhibitor as the brand name for recognizing the National Football League's top offensive lineman, with former NFL coach John Madden also putting his name on the award. The firm Nov. 12 said the Madden Most Valuable Protectors Award will go to "the loyal protectors who serve as the backbone of every NFL team." Consumers can vote for the award winner online -www.MaddenProtectorsAward.com - during the NFL playoffs in January. Selection of the winner will also take into account statistics from the full season and opinions from the NFL, according to the release. The award will be presented during the week of Super Bowl XLIV, Feb. 7, in Miami

You may also be interested in...



P&G Creates Prilosec OTC Social Network To "Sponsor Everything You Do"

Analysts say the firm is on target appealing to consumers' emotions, and interactive online marketing is beginning to reach across the gamut of consumers.

P&G Creates Prilosec OTC Social Network To "Sponsor Everything You Do"

Procter & Gamble aims to gain market share for its proton pump inhibitor Prilosec OTC by harnessing the power of interactive digital media and social networking to build consumers' emotional connections to the product

NZ Govt Moves To Speed Drug Access While Planning To Wipe Out Major New Act

A parallel assessment mechanism that will allow new medicines in any therapeutic area to be considered for funding sooner is being introduced in New Zealand, where the new coalition government is working to repeal last year’s landmark Therapeutic Products Act.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel